2452. Treatment and Outcomes of Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

BACKGROUND: Daptomycin (dap) is approved as an alternative to vancomycin (van) for therapy of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI). Cases of therapy failure associated with the emergence of daptomycin-nonsusceptible (DNS) MRSA strains have been documented. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Hadid, Hind, Bardossy, Ana Cecilia, Misikir, Helina, Perri, Mary Beth, Zervos, Marcus, Herc, Erica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255085/
http://dx.doi.org/10.1093/ofid/ofy210.2105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255085/
http://dx.doi.org/10.1093/ofid/ofy210.2105

Ejemplares similares